Miguel Ángel
Hernández Pérez
Professeur Assistant à Temps Partiel (Sciences de la Santé)
University College London
Londres, Reino UnidoPublications en collaboration avec des chercheurs de University College London (1)
2018
-
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415